Enhanced treatment of liver carcinoma with a drug-eluting hydrogel.

Scientists from the Terasaki Institute for Biomedical Innovation have developed a drug-eluting hydrogel that can enhance the treatment of hepatocellular carcinoma (HCC), a deadly form of liver cancer. The hydrogel provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The researchers tested the hydrogel in mouse models and found that the subjects treated with the combined drug-loaded hydrogels had the longest survival times and smallest tumor size. This approach offers hope for patients with HCC and improves current treatment methods. [Extracted from the article]